When should cervical cancer screening with Pap smear (or Pap plus HPV testing) be discontinued, and what factors (e.g., prior hysterectomy, high‑grade dysplasia, immunocompromise) would require continuation beyond age 65?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cervical Cancer Screening Discontinuation

Discontinue cervical cancer screening at age 65 years if adequate prior screening has been documented and there is no history of high-grade dysplasia (CIN 2/3) or cervical cancer in the past 25 years.

Criteria for Screening Cessation at Age 65

The decision to stop screening requires meeting all of the following criteria 1:

  • Age ≥66 years (meaning screening stops after age 65)
  • Adequate negative prior screening defined as:
    • 2 consecutive negative HPV tests, OR
    • 2 consecutive negative cotests (HPV + cytology), OR
    • 3 consecutive negative cytology tests
    • All within the past 10 years
    • Most recent test within the recommended interval for that test type
  • No history of CIN 2/3 or cervical cancer in the past 25 years 1
  • Not currently under surveillance for abnormal results

If documentation of adequate prior screening is unavailable, continue screening until exit criteria are met 1.

Populations Requiring Continued Screening Beyond Age 65

Absolute Indications to Continue Screening

Never discontinue screening in these populations, regardless of age 2, 1:

  • History of high-grade precancerous lesions (CIN 2/3) within the past 25 years
  • History of cervical cancer (any time)
  • HIV infection or other immunocompromise (solid organ transplant, stem cell transplant, chronic immunosuppressive therapy) 1, 3
  • In utero diethylstilbestrol (DES) exposure 2, 1

These patients require lifelong screening due to persistently elevated risk of HPV persistence, reactivation, and accelerated progression to malignancy 3, 4.

Inadequate Prior Screening

Continue screening if the patient:

  • Has not met the 10-year lookback criteria above
  • Has gaps in screening history
  • Has unknown or undocumented screening history 1, 5

Common pitfall: Most women over 65 discontinue screening without meeting exit criteria 6, 5. In one study, only 5.2% of high-risk women were appropriately screened 6.

Special Populations

Post-Hysterectomy

Discontinue screening if hysterectomy included cervical removal AND there is no history of CIN 2/3 or cervical cancer 2, 7.

Continue screening if:

  • Supracervical hysterectomy (cervix retained) 1
  • Hysterectomy performed for CIN 2/3 or cancer 2
  • HIV-positive: annual vaginal cuff cytology recommended 3

Immunocompromised Patients

These patients require more intensive, lifelong screening 3, 4:

  • HIV-positive women: Annual cytology starting at diagnosis, with colposcopy for any abnormality 3
  • Transplant recipients: Annual screening, though specific protocols vary 3
  • Autoimmune disease on immunosuppression: Guidelines are less established but increased surveillance is warranted 3

The evidence shows these populations have higher rates of persistent HPV infection, multifocal disease, recurrence, and progression to HSIL and invasive cancer 4.

Screening Modalities at Older Ages

For women who continue screening beyond 65 (due to not meeting exit criteria), the preferred approach is 1:

  • Primary HPV testing every 5 years (preferred)
  • Cotesting (HPV + cytology) every 5 years (acceptable)
  • Cytology alone every 3 years (acceptable if HPV testing unavailable)

Recent evidence suggests HPV-based strategies and self-sampling may improve participation in older women, particularly those with incomplete prior screening 8. Self-sampling addresses barriers related to postmenopausal anatomy and speculum discomfort 8.

Key Clinical Caveats

  1. Age 65 is not automatic cessation: The age threshold only applies if all other criteria are met 1, 5

  2. The 25-year lookback for high-grade lesions: A history of CIN 2/3 treated 20 years ago still requires continued screening 1

  3. Limited life expectancy: Screening may be discontinued at any age if life expectancy is significantly limited 1

  4. Risk of inadequate documentation: When in doubt, continue screening until adequate negative results are documented prospectively 1, 5

  5. Immunocompromised patients are never candidates for cessation: This is an absolute contraindication regardless of age or prior screening 1, 3

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.